Clearpoint Neuro Inc reports results for the quarter ended June 30 - Earnings Summary

Clearpoint Neuro

03/08/2026 22:38

Clearpoint Neuro Inc CLPT.OQ reported a quarterly adjusted loss of 38 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -21 cents.  The mean expectation of three analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -33 cents to -25 cents per share.
Revenue rose 18.1% to $10.88 million from a year ago; analysts expected $12.73 million. 
Clearpoint Neuro Inc's reported EPS for the quarter was a loss of 38 cents​.
The company reported a quarterly loss of $11.34 million.
Clearpoint Neuro Inc shares had fallen by 16.3% this quarter and gained 9.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 12.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Clearpoint Neuro Inc is $30.00, about 50.2% above its last closing price of $14.94
This summary was machine generated from LSEG data August 3 at 09:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.29
-0.38
Missed
Mar. 31 2026 
-0.27
-0.32
Missed
Dec. 31 2025 
-0.20
-0.26
Missed
Sep. 30 2025 
-0.20
-0.21
Missed